A curated, source-verified library of the strongest available research on harm reduction, treatment outcomes, overdose prevention, and the comparative effectiveness of voluntary versus coercive addictions care. Every entry links to a peer-reviewed journal, government report, university source, or major public-health agency.
Economic evaluations, return-on-investment analyses, and healthcare-system cost studies.
Showing 10 of 10 entries
International Journal of Drug Policy · Andresen MA, Boyd N
Economic evaluation finds Insite produces a net societal benefit, primarily by averting HIV infections and overdose deaths.
Benefit-cost ratio of 5.12 ($5 in savings per $1 spent).
International Journal of Drug Policy · Pinkerton SD
Models the HIV infections averted by Insite each year; converts to lifetime treatment-cost savings.
~35 HIV infections averted/year → ~$6M+ lifetime treatment savings.
CCSA / CISUR
Most current national accounting of healthcare, lost-productivity, criminal justice, and other societal costs attributable to substance use, with provincial breakdowns.
$49.1B/year total; opioids alone accounted for $7.1B in 2020.
JAMA Psychiatry · Fairley M, Humphreys K, Joyce VR, et al.
Decision-analytic model: methadone, buprenorphine, and naltrexone are all cost-effective vs. no treatment; methadone has the lowest incremental cost-effectiveness ratio.
American Journal of Public Health · Coffin PO, Sullivan SD
Naloxone distribution to people who use opioids is cost-effective at $438 per QALY gained — well below standard thresholds.
CMAJ Open · Latimer EA, Rabouin D, Cao Z, et al.
At Home/Chez Soi cost analysis: every $10 invested in Housing First saved $9.60 for high-needs participants and $3.42 for moderate-needs participants.
Up to $0.96 returned per $1 invested in Housing First for high-needs.
CMAJ · Nosyk B, Guh DP, Bansback NJ, et al.
Economic analysis of NAOMI: prescribed diacetylmorphine is cost-effective compared with methadone for treatment-refractory opioid dependence.
Addiction · Irvine MA, Kuo M, Buxton JA, et al.
BC modelling: take-home naloxone, SCS, and OAT scale-up averted an estimated 3,030 deaths between 2012–2017.
Addiction · Krebs E, Urada D, Evans E, et al.
Publicly funded OUD treatment substantially reduces criminal-justice costs during and after care.
Canadian Centre on Substance Use and Addiction
CCSA / CISUR Saskatchewan provincial brief on the healthcare and broader costs of substance-use disorders.
Curated and maintained by Voluntary Treatment First Saskatchewan. Every entry links to a peer-reviewed journal, government report, university, or major public-health agency. Spot a broken link or missing study? Let us know.
